Compare Cytokinetics Inc (CYTK) vs Public Storage (PSA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Public Storage — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while Public Storage trades at $289.86 (market cap $53.35B). The key difference: Public Storage is far larger — about 6.2× Cytokinetics Inc's market cap, and Public Storage pays a 4.2% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Public Storage for 130 Days on average.
| CYTK | PSA | |
|---|---|---|
Market Cap | $8.62B | $53.35B |
Volume | 2,594,626 | 1,176,034 |
Sector | Health | Real Estate |
52-Week High | $87.26 | $330.47 |
52-Week Low | $54.76 | $258.44 |
Typical Hold Time | 19 Days | 130 Days |
Enterprise Value | $8.72B | $67.62B |
Dividend Yield | — | 4.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported Q2 2026 EPS of -$1.50, beating expectations, but maintains deeply negative profitability with a net income margin of -1,321.12% for 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy studies and presentations at major medical conferences.
Wall Street sentiment is overwhelmingly bullish with a 97.14% buy rating and a $112.60 consensus price target, signaling strong upside potential. However, high cash burn, substantial losses, and significant debt-to-asset ratio of 81.23% present substantial financial risks. Investment appeal hinges on successful commercialization of its pipeline amid intense competition.
Public Storage (PSA) trades at $285.52, up 1.25% with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with 41.8% net margins and 37.42% ROE, though valuation metrics appear elevated with P/E of 27.24 and P/S of 10.28. Recent developments include the completion of Public Storage Canada acquisition and a $400 million Canadian bond offering, while cash flow trends show consistent operational strength despite negative net flows.
PSA presents a mixed outlook with strong fundamentals offset by premium valuation. The 4.05% dividend yield and improving operational metrics support income investors, but technical weakness and high multiples create near-term headwinds. Key risks include REIT sector sensitivity to interest rates and competitive pressures in the self-storage market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Public Storage
Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.
Read more on PSA →
